AMRN · XBRL financial data

Amarin financial statements, every fiscal year

The same tables from 6 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (AMRN's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Revenue from contracts with customers	614	583	369	307	229	214
Cost of goods and services sold	131	121	—	—	—	—
Gross profit	483	462	242	166	81	121
Research and development	39	29	30	22	21	20
Selling, general and administrative	463	408	304	200	152	115
General and administrative	—	—	75	53	38	44
Total operating expenses	502	451	348	233	173	171
Operating income (loss)	(20)	11	(106)	(68)	(92)	(50)
Interest income	5	1	3	12	13	11
Interest expense	3	0	0	0	0	0
Other income (expense)	0	(0)	(1)	2	1	3
Income tax expense (benefit)	1	4	2	5	5	3
Net income (loss)	(18)	8	(106)	(59)	(82)	(39)
Earnings per share, basic USD per share	(0.05)	0.02	(0.26)	(0.15)	(0.20)	(0.09)
Earnings per share, diluted USD per share	(0.05)	0.02	(0.26)	(0.15)	(0.20)	(0.09)
Weighted average shares, basic millions of shares	382	396	401	408	411	415
Weighted average shares, diluted millions of shares	382	402	401	408	411	415

Fiscal years (AMRN's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	187	219	218	199	121	135
Short-term investments	314	235	92	121	173	168
Accounts receivable	155	164	131	134	122	127
Inventory	189	235	229	259	166	196
Prepaid and other current assets	31	22	19	12	13	24
Total current assets	879	879	689	725	595	650
Property and equipment, net	2	1	1	0	0	0
Right-of-use asset	8	8	9	8	8	6
Total assets	966	1,068	886	832	685	671
Accounts payable	106	115	65	53	40	45
Current portion of long-term debt	0	0	—	—	—	—
Total current liabilities	307	371	259	259	180	194
Lease liability, non-current	9	9	10	9	8	6
Total liabilities	339	401	291	280	199	211
Accumulated deficit	(1,429)	(1,421)	(1,527)	(1,586)	(1,669)	(1,707)
Total stockholders' equity	628	667	595	552	486	459
Total liabilities and equity	966	1,068	886	832	685	671
Common shares outstanding (cover page) millions of shares	393	397	404	409	412	416

Fiscal years (AMRN's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	(18)	8	(106)	(59)	(82)	(39)
Stock-based compensation	46	37	26	16	18	14
Net cash from operating activities	(22)	(67)	(180)	7	(31)	7
Purchases of property and equipment	0	—	—	—	—	—
Net cash from investing activities	(377)	104	175	(26)	(46)	9
Repayments of long-term debt	50	—	—	—	—	—
Net cash from financing activities	(59)	(5)	(0)	0	(1)	(2)
Net change in cash	(458)	32	(5)	(18)	(78)	14

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($M)	Revenue, quarter ($M)	Operating cash flow, quarter ($M)	Shares outstanding	Runway	Quarter
Amarin	157	40	9.2*	not reported	—	Q3 FY26 10-QSep 30, 2026
Rigel Pharmaceuticals	61	79	31*	18.7M	—	Q2 FY26 10-QJun 30, 2026
Northwest Biotherapeutics	0.6	0.8	(7.2)*	1.7B	0.1 quarters	Q2 FY26 10-QJun 30, 2026
Usana Health Sciences	169	223	23*	18.5M	—	Q2 FY26 10-QJul 4, 2026
Emergent BioSolutions	176	110	100*	51.4M	—	Q3 FY26 10-QSep 30, 2026
Altimmune	63	not reported	(24)*	194.5M	13.5 quarters	Q2 FY26 10-QJun 30, 2026
Prothena Corp Public	288	1	(25)*	51.3M	11.5 quarters	Q2 FY26 10-QJun 30, 2026
Aura Biosciences	68	not reported	(33)*	103.7M	2.1 quarters	Q2 FY26 10-QJun 30, 2026
Nektar Therapeutics	39	10	(76)*	34.1M	9.0 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.